KBI Biopharma (KBI), a cGMP contract development and manufacturing organisation (CDMO), and the biotechnology company Infinimmune, have announced a collaboration to advance Infinimmune’s lead human monoclonal antibody (IFX-101) programme.
Infinimmune pioneers novel human-first antibody discovery and development, building its own pipeline of drug candidates designed to have improved safety and efficacy.
The first antibody in the company's therapeutic drug development pipeline, IFX-101, targets atopic dermatitis and is designed to deliver superior efficacy with extended dosing intervals for improved patient quality of life.
Rather than engineering antibodies from scratch, Infinimmune sources antibodies directly from the human immune system, tapping into a naturally optimised and safe therapeutic reservoir.
Its GLIMPSE platform – a protein language model trained solely on native human antibody sequences – learns from millions of successful immune responses to create superior antibodies that use evolution-proven strategies alongside enhanced biologic properties.
This combination creates a powerful platform that’s uniquely differentiated in the biologics field.
“We are pleased to partner with KBI Biopharma to advance our lead antibody programme,” said Wyatt McDonnell, PhD, CEO and founder, Infinimmune.
“By combining our Anthrobody and GLIMPSE platforms together with KBI’s development and manufacturing expertise, we’re positioned to rapidly advance toward clinical trials."
"Our human-first approach enables us to deliver what patients really need – more effective treatments with greater convenience. This collaboration is an important step in our mission to bring transformative, human-first antibodies to patients in need."
Katie Edgar, Chief Business Officer of KBI Biopharma, added: “KBI is proud to support Infinimmune in its effort to transform biologics and deliver safer, more effective antibody therapeutics.”
“Our strategic partnership will be highly synergistic in biologics development, by combining Infinimmune’s cutting-edge antibody discovery with KBI’s deep expertise in development and manufacturing capabilities.”
The IFX-101 programme is advancing at KBI’s Cell Line Development Centre of Excellence in Geneva, Switzerland, using KBI’s advanced monoclonal antibody development and manufacturing platform, SUREmAb, powered by Selexis.